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ABSTRACT
Introduction. The dose-dependent adverse events associated with 
post-operative opioid use may be reduced when opioids are used in 
conjunction with intravenous acetaminophen. The purpose of this 
study was to compare outcomes in median sternotomy patients 
receiving intravenous acetaminophen in addition to intravenous 
opioids versus intravenous opioids only.
Methods.xA retrospective study was conducted on 122 adult patients 
undergoing median sternotomy at a regional tertiary-referral center. 
Data collected included patient demographics, length of stay, opioid 
and intravenous acetaminophen use, adverse effects, and transition 
time to oral pain medication.
Results. There was no difference between groups in demographics, 
preoperative risk scores, operative procedures, intravenous opioid 
consumption, transition time to oral pain medications, or length of 
stay. Acetaminophen use was associated with lower rates of atrial 
fibrillation (7.0% vs. 24.6%, p = 0.009) and nausea/vomiting (8.9% 
vs. 32.3%, p = 0.002), but higher rates of urinary retention (15.8% 
vs. 3.1%, p = 0.014), constipation (50.0% vs. 20.0%, p = 0.001) and 
respiratory depression (7.1% vs. 0.0%, p = 0.043).
Conclusion. Intravenous acetaminophen was not associated with 
a reduction in length of stay or opioid consumption, but was asso-
ciated with lower rates of atrial fibrillation, nausea, and vomiting. 
Additional studies are needed to determine if intravenous acetamin-
ophen administration reduces atrial fibrillation in this population.
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INTRODUCTION
The treatment of post-operative pain from median sternotomy in 
cardiac surgery patients has consisted primarily of opioid administra-
tion. Although effective, opioids are associated with dose-dependent 
adverse effects and negative outcomes possibly increasing length of 
hospital stay and subsequent healthcare costs.1 Some of the common 
adverse effects associated with opioid use include respiratory depres-
sion, ileus, nausea, urinary retention, constipation, sedation, and 
addiction.1,2 Multimodal analgesia approaches to post-operative pain 
management can minimize the undesirable adverse effects associ-
ated with the sole use of opioids.3,4
Intravenous acetaminophen (IA) received U.S. Food and Drug 
Administration approval in November 2010. It is a centrally acting 
analgesic and antipyretic. Intravenous acetaminophen has a very 
favorable side-effect profile and does not alter platelet aggregation 
factors or impose significant drug-drug interaction. Some of its 
common adverse effects include nausea, vomiting, headaches, and 
insomnia.5 A vial of IA costs approximately $45.00 per dose, whereas 
intravenous (IV) and oral narcotics cost approximately $0.25 per 
dose at our facility. Although expensive, the use of IA could offset 
its associated cost-increase by reducing undesirable adverse effects, 
thereby shorten the length of hospital stays.5
Since its approval for use, studies in the gynecology and colorectal 
literature have shown reduced post-operative nausea and vomiting 
(PONV) and decreased hospital length of stay with the use of IA 
and adjunctive opioid analgesics in post-operative patients.6,7 To our 
knowledge, only one study has been performed in post-operative 
cardiac patients in the United States to assess the efficacy of IA as 
an adjunct analgesic to opioids, but this study did not demonstrate a 
decrease in length of hospital stay as seen in other studies.8
The purpose of this study was to compare the length of hospi-
talization between median sternotomy patients who received IA 
in conjunction with oral and IV narcotics vs. IV and oral narcotics 
alone in the peri-operative period. Secondary data gathered in the 
study were used to compare IV opiate consumption, IA consumption, 
adverse effects, and time to transition from IV to oral pain medica-
tion.
METHODS
We conducted a case-controlled, retrospective chart review of 
adult patients who presented to one midwestern tertiary-care hospi-
tal for non-emergency open cardiac surgery via median sternotomy 
from June 2014 to December 2015. In-hospital pharmacy records 
were searched to generate a list of all patients who underwent non-
emergency open cardiac surgery via median sternotomy and received 
IA on the cardiothoracic intensive care unit (ICU) or floor during 
the study time period. The resultant patients were matched with 
case-control patients who underwent non-emergency open cardiac 
surgery via median sternotomy and did not receive IA in the post-
operative period. Cases and controls were matched based on age, sex, 
race, and body mass index. Patient charts were reviewed to collect 
additional data for analysis.
Data collected included patient’s age, race/ethnicity, gender, body 
mass index, pertinent medical history, preoperative risk score, IV 
and oral opiate consumption, IA consumption, adverse effects, time 
to transition from IV to oral pain medication, and hospital outcomes 
(ICU days, ventilator days, and hospital length of stay). Patient 
medical histories were reviewed to exclude patients who were on 
scheduled narcotics or had a history of narcotic dependence prior to 
surgery. Patients with severe hepatic impairment also were excluded. 
Severe hepatic impairment was defined as a Child class B or C.
All doses of opioids administered during the hospitalization were 
tallied and converted to milligrams of morphine based on opioid 
equivalence per day. Intravenous acetaminophen was measured 
in milligram per day and was administered post-operatively every 
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tions (opioids and IA) administered in the peri-operative time period 
were quantified until each patient was discharged from the hospital.
Statistical Analysis. Comparisons of qualitative and quantitative 
data between subgroups were compared using chi-square analysis 
and analysis of variance. Non-parametric comparisons were used 
when assumptions for data distributions could not be met. All statisti-
cal tests were two-sided and considered statistically significant when 
p ≤ 0.05. All analyses were conducted using SPSS release 19.0 (IBM 
Corp., Armonk, New York).
This study was approved for implementation by the Institutional 
Review Board of Via Christi Hospitals Wichita Inc.
RESULTS
A total of 146 patient charts were reviewed for study inclusion (n 
= 73 for each group). Of those, eight patients were excluded from the 
opioids only group; one with a history of severe hepatic impairment 
and seven for narcotic dependence. Seventeen patients were excluded 
from the opioids + IA group for a history of narcotic dependence. One 
patient underwent two surgeries in which opioid and IA were used 
in the post-operative period, so their second surgery was considered 
a separate case for analysis. The total number of patients included 
in analysis after exclusions was 122, with 65 patients (53.3%) in the 
opioid only group, and 57 patients (46.7%) in the opioids + IA group.
Demographics, pertinent past medical history, and preoperative 
risk scores were not significantly different between groups, though 
there was a trend for higher risk patients to have received IA (Table 1). 
Intravenous opioids administered and time to transition to oral pain 
regimen were not different between study groups (Table 2). Patients 
who received IA had higher rates of respiratory depression (7.1% vs. 
0.0%, p = 0.043), urinary retention (15.8% vs. 3.1%, p = 0.014), and 
constipation (50.0% vs. 20.0%, p = 0.001). However, there was a sig-
nificant reduction in the incidence of PONV with the use of IA (8.9% 
vs. 32.3%, p = 0.002). Additionally, there was a significant decrease in 
the incidence of atrial fibrillation in patients that received IA in con-
junction with opioids (7.0% vs. 26.2%, p = 0.005) as shown in Table 2. 
When looking only at patients that had undergone a coronary artery 
bypass graft (CABG) procedure, the decreased incidence of atrial 
fibrillation in patients that received IA in conjunction with opioids 
remained significant (7.3% vs. 29.3%, p = 0.010). Other less common 
adverse events associated with each group are shown in Table 3. A 
breakdown of procedures performed in patients in the opioid only 
group and the IA group are shown in Table 4.
The primary study outcome was length of hospital stay. Our data 
did not demonstrate a clinically significant reduction in median 
length of hospital stay with use of adjunct IA compared with opioid 
use alone (6 vs. 6 days respectively, p = 0.059; Table 5). Intensive 
care unit days, and ventilator days were also similar between the two 
groups.
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Table 1. Demographics and pertinent medical history of indi-
viduals who received opioid only or opioid with intravenous 
acetaminophen following median sternotomy.*
Parameter Opioid only group Opioid + IA group p-Value
Number of 
observations 65 (53.3%) 57 (46.7%) ---
Age (years) 67.3 ± 11.1 68.5 ± 9.7 0.544
Body mass index 29.6 ± 5.2 29.5 ± 6.6 0.954
Male sex 50 (76.9%) 36 (63.2%) 0.096
Race† 0.465
  White 58 (92.1%) 49 (89.1%)
  Black 2 (3.2%) 1 (1.8%)
  Asian 3 (4.8%) 3 (5.5%)
  Hispanic 0 (0.0%) 2 (3.6%)
History of hepatic 
impairment 1 (1.5%) 1 (1.8%) > 0.999
Preoperative Risk 
Score‡ 0.013 (0.007,0.020) 0.017 (0.010,0.030) 0.083
*Data are presented as N (%), mean ± standard deviation, or median (25th, 
75th percentiles).
†Two patients from each group chose not to disclose race.
‡Risk score values based on 48 individuals in the opioid only group and 46 
individuals in the opioid and IA group.
Table 2. Pain management and adverse effects for individuals 
who received opioid only or opioid with intravenous acetamino-
phen following median sternotomy.*
Parameter Opioid only group Opioid + IA group p-Value
Number of 
observations 65 (53.3%) 57 (46.7%) ---
IV opioid 
consumption 
(mg in morphine 
equivalents)
14 (4,27) 14 (8,24) 0.470
IA consumption (g) n/a 6.1 ± 2.1 n/a
Time to transition 
to oral pain 
medications (hr)
31 (10,51.5) 38 (16.5,65) 0.399
Post-operative 
nausea/vomiting 21 (32.3%) 5 (8.9%) 0.002
Atrial fibrillation 17 (26.2%) 4 (7.0%) 0.005
Constipation 13 (20.0%) 28 (50.0%) 0.001
Urinary retention 2 (3.1%) 9 (15.8%) 0.014
Respiratory 
depression 0 (0.0%) 4 (7.1%) 0.043
Ileus 0 (0.0%) 0 (0.0%) n/a
Other adverse 
effects 7 (10.8%) 6 (10.5%) 0.965
*Data are presented as N (%), mean ± standard deviation, or median (25th, 
75th percentiles). 
†Fisher’s exact test used due to expected cell counts <5.
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Table 3. A list of “other adverse effects” for individuals who 
received opioid only or opioid with intravenous acetaminophen 
following median sternotomy.
Study group Other adverse effects
Opioid only group (n=7) Confusion (4)
Lightheadedness (2)
Ventricular tachycardia (1)
Opioid + IA group (n=6) Dizziness (1)
Headache (1)
Bronchitis (1)*
Acute kidney injury (1)*
Clostridium difficile (1)
Death (2)
*Bronchitis and acute kidney injury were experienced by the same patient.
Table 4. Operative procedures for individuals who received 
opioid only and opioid with intravenous acetaminophen follow-
ing median sternotomy.
Procedure(s) Opioid only Group
N (%)
Opioid + IA group
N (%)
Number of observations 65 (53.3%) 57 (46.7%)
CABG 41 (63.1%) 41 (71.9%)
AVR 7 (10.8%) 7 (12.3%)
MVR 0 (0.0%) 2 (3.5%)
CABG + AVR 6 (9.2%) 1 (1.8%)
CABG + MVR 0 (0.0%) 1 (1.8%)
CABG + valve +RFA/LAA 3 (4.6%) 2 (3.5%)
CABG+ RFA/LAA 4 (6.2%) 0 (0.0%)
CABG + MVR +AVR 0 (0.0%) 2 (3.%)
MVR + AVR 1 (1.5%) 0 (0.0%)
MV + RFA/LAA 1 (1.5%) 0 (0.0%)
Other 2 (3.1%) 1 (1.8%)
CABG = coronary artery bypass graft; AVR = aortic valve replacement; MVR 
= mitral valve replacement; RFA = radio frequency ablation; LAA = left atrial 
appendage; MV = mitral valve.
Table 5. A comparison of length of stay outcomes for individuals 
who received opioid only or opioid with intravenous acetamino-
phen following median sternotomy.*
Parameter Opioid only group Opioid + IA group p-Value
Number of 
observations 65 (53.3%) 57 (46.7%) ---
Intensive care 
unit days 3 (2,4) 2 (2,4) 0.286
Ventilator days† 1 (1,4) 1 (1,2.5) 0.758
Hospital length 
of stay 6 (5,7) 6 (5,8) 0.059‡
*Data are presented as N (%), or median (25th, 75th percentiles).
†Only individuals with non-zero values used for analysis.
‡Test of medians with Yates correction for continuity.
DISCUSSION
Analgesic and Opiate Consumption Effects. Studies on the 
efficacy of IA have demonstrated conflicting results. For example, 
Cattabriga et al.9 demonstrated a significant improvement in anal-
gesic effect with IA within the first 24 hours and a 49% reduction 
in cumulative morphine consumption within the first three days in 
post median sternotomy patients. Other studies also have found a 
significant reduction in mean opioid consumption in otorhinolaryn-
gology and gynecology patients who received IA.6,10 Those studies 
were inconsistent with our results, as we found no change in the 
cumulative opioid consumption with adjunctive IA use. Similar to 
our study, others have demonstrated no reduction in the mean opioid 
consumption with addition of IA.7,11 This discrepancy in results could 
be explained by the lack of standardization of IA administration. In 
our study, the total duration of the IA administration varied between 
patients, ranging anywhere between 24-48 hours (4-8g of IA), partly 
due to the financial implications associated with the IV formulation. 
According to Remy et al.,12 the typical administration of 1 g of IA every 
six hours, as described in many of the studies reviewed, has less than 
10 mg sparing effect on IV opioid consumption over a 24-hour period. 
A study by Juhl and colleagues supported this theory by demonstrat-
ing that 2 g IA every six hours (total daily dose maximum of 8 g) was 
superior to 1 g of IA every six hours in terms of efficacy and analge-
sia.13 This is important, as it may explain why opioid consumption 
was not found to decrease given the lower dose of analgesia achieved 
by 1 g of IA in our study. Hence, a stronger dose of IA every six hours 
may be needed to reach an effective therapeutic dose as suggested by 
Remy et al.2
Hospital Length of Stay Effects. Two non-cardiac surgery 
studies demonstrated a significantly shorter hospital length of stay 
of one to two days with the use of IA compared to placebo.6,14 The 
only U.S. cardiac study by Mamoun et al.7 revealed no effect on hos-
pital length of stay in addition to ventilation days, ICU, or opioid 
consumption with adjunct use of IA, which is similar to our results. 
The discrepancy of the length of hospital stay likely is due to the dif-
ferent patient populations; inherently cardiac surgery patients have 
higher peri-operative risk scores and worse co-morbidities that are 
less likely to be affected by the addition of IA or reduction of opioid 
consumption.
Post-operative Nausea and Vomiting Effects. We demonstrated 
a significant reduction in PONV with the use of IA consistent with 
the meta-analysis performed by Apfel and colleagues.15 However, 
the amount of opioids administered did not differ between the two 
groups. This contradicted the study performed by Lahtinen and col-
leagues16, who demonstrated decreased opiate consumption in the 
first 24 hours, but no difference in PONV, with the administration of 
Propacetamol, a prodrug of acetaminophen. Although our study did 
not measure pain scores, the combination of IA and opioids possibly 
provided more effective analgesia, which is believed to decrease the 
incidence of PONV indirectly. In addition, according to Apfel et al.15, 
IA given prophylactically in a scheduled manner has been shown to 
be effective in reducing PONV. They further suggested that IA has a 
direct antiemetic effect on the brain leading to less PONV.
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respiratory depression were significantly higher in the IA group, which 
has not been demonstrated in other studies. Adverse effects of IA less 
than 1%, according to its manufacturer’s label, included respiratory 
atelectasis, pulmonary edema, and constipation. Although those are 
very low percentages, the use of opioids in conjunction with IA may 
have synergistic effects that could potentiate those adverse effects.
Atrial Fibrillation Reduction. Incidentally, we observed a lower 
occurrence of atrial fibrillation in the group receiving IA, an effect 
that has not been reported in other studies with IA. Both groups had 
similar indications and preoperative risk factors, which in theory 
should minimize confounding factors. Interestingly, according to 
animal studies, acetaminophen has been found to have cardioprotec-
tive and antiarrhythmic effects by attenuating release of free radicals 
due to oxidative injuries.17,18 According to Chang et al.19, the addition 
of IA may inhibit nitric oxide release, which would enhance diastolic 
tension thereby resulting in improved inotropic effect and improved 
electromechanical cardiac activity leading to less cardiac arrhyth-
mias. Whether IA plays a definite role in the prevention of atrial 
fibrillation in post cardiac surgery patients remains to be evaluated 
in a prospective study.
Limitations. Being a retrospective study, we were limited to the 
data available to us at this institution and some data points were 
missing in a few patients such as preoperative risk factors. Further-
more, there was a concern for selection bias by the surgeons, as we 
noted earlier a trend for higher risk patients to receive IA. In addi-
tion, although we excluded patients with history of narcotic use, the 
accuracy of medical records or reliability of individuals could be 
questioned as well. Moreover, the administration of IA was not stan-
dardized. Hence, a larger prospective study that compares several 
administration protocols is necessary to establish a safe effective 
therapeutic dose. Lastly, our observation of decreased rates of atrial 
fibrillation was incidental and should be further studied in humans 
to confirm such findings. Although it may prove initially to be costly, 
the use of prophylactic IA to prevent atrial fibrillation may offset its 
associated cost-increase in the long run. A prospective randomized 
controlled trial is needed to validate this hypothesis.
CONCLUSIONS
 Intravenous acetaminophen was not associated with a reduction in 
the length of hospital stay or intravenous opioid consumption in post-
median sternotomy patients at this community-based, tertiary-care 
facility. However, IA was associated with a reduction in other adverse 
side effects such as atrial fibrillation and PONV. The use of IA may 
play a role in atrial fibrillation prevention; however, additional studies 
are needed to support this conclusion. 
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